Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant – Successful Launch of Advanced Automated Workstation at BASF

XtalPi and VISEN Pharmaceuticals Enter Strategic Partnership to Co-Develop Innovative Endocrine Therapies for a Multi-Billion Dollar Market

XtalPi Partners with Mirxes and Signet Therapeutics to Launch Global “AI Screening + Precision Treatment” Closed-Loop System for Gastric Cancer

XtalPi-Powered ReviR Therapeutics Secures Additional NMPA Clinical Approval for “AI+RNA” Rare Disease Pipeline RTX-117

XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision

XtalPi and Sunshine Lake Pharma Enter Strategic Partnership to Accelerate “AI + Robotics” Drug Discovery Paradigm

XtalPi-Incubated Leman Biotech Unveils Breakthrough CAR-T Results at J.P. Morgan Healthcare Conference: 100% CR in SLE Patients at 0.1% of Standard Dose

JPM 2026 Recap | XtalPi Showcases at the Global Stage: Redefining Drug Discovery with AI + Robotics

XtalPi and Signet Therapeutics Announce IND Filing for Potential First-in-Class TEAD Inhibitor SIGX2649

XtalPi Secures Major Milestone Payment as Incubated “AI + RNA” Pipeline Exceeds Expectations

Powerhouse Collaboration: XtalPi and JinkoSolar Form Joint Venture to Push Photovoltaic Efficiency Limits with AI

XtalPi Empowers China’s First “AI + RNA” Small Molecule Pipeline to Enter Clinical Trials; ReviR Therapeutics Achieves Breakthrough in First-in-Class Rare Disease Drug